brain-cancer

Nanobody targeting immune protein HVEM suppresses the most treatment-resistant form of glioblastoma in mice

Glioblastoma (GBM) is one of the most lethal cancers, and its mesenchymal subtype — characterized by inflammation and resistance to standard therapy — is particularly hard to treat. Researchers found that a protein called HVEM (herpes virus entry mediator) is highly expressed specifically in mesenchymal GBM cells, where it drives tumor growth, invasion, and treatment resistance through NF-κB signaling.

To block HVEM, the team engineered nanobodies — tiny antibody fragments derived from camel immune cells — that bind to a specific part of HVEM. These nanobodies suppressed tumor cell invasion in lab cultures and shrank tumors in mouse xenograft models. Critically, the nanobody also blocked HVEM's interaction with BTLA, a checkpoint protein that helps tumors evade immune attack — suggesting the therapy could work by both directly killing tumor cells and restoring immune surveillance.

HVEM also conferred resistance to chemotherapy drugs, and removing it restored drug sensitivity.

Key Findings

HVEM is highly expressed in mesenchymal GBM and promotes proliferation, neurosphere formation, and invasion
APRIL ligand activates HVEM → NF-κB → mesenchymal transition in GBM cells
HVEM expression contributes to anticancer drug resistance; knockout restored sensitivity
Anti-HVEM nanobody suppressed invasion in organotypic cultures and tumor growth in mouse xenograft
Nanobody blocks HVEM-BTLA interaction, potentially restoring immune surveillance in addition to direct anti-tumor effects

Implications

HVEM is a compelling new target in GBM — especially mesenchymal GBM, which currently lacks effective targeted therapies. The dual mechanism (direct anti-tumor + immune checkpoint restoration) is particularly attractive. Nanobodies are well-suited for brain tumors due to their small size and potential CNS penetration. This could inform a new class of GBM immunotherapy.

Caveats

Preprint — not peer reviewed. In vivo data is from mouse xenograft models, which have limited predictive value for GBM trials. Nanobody is anti-human HVEM; clinical development pipeline is early. No human data. GBM trials have a very high failure rate due to the blood-brain barrier and tumor heterogeneity.

Source: bioRxiv — 2026-04-07

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.